Galectin Therapeutics Inc (NASDAQ: GALT) on Friday, plunged -28.90% from the previous trading day, before settling in for the closing price of $6.16. Within the past 52 weeks, GALT’s price has moved between $0.73 and $7.13.
A company in the Healthcare sector has dropped its sales by -23.89% annually for the last half of the decade. The company achieved an average annual earnings per share of 35.53%. With a float of $45.96 million, this company’s outstanding shares have now reached $64.47 million.
Galectin Therapeutics Inc (GALT) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Galectin Therapeutics Inc is 28.81%, while institutional ownership is 15.94%. The most recent insider transaction that took place on Dec 17 ’25, was worth 55,241. In this transaction President and CEO of this company sold 7,829 shares at a rate of $7.06, taking the stock ownership to the 832,592 shares. Before that another transaction happened on Dec 17 ’25, when Company’s Chief Medical Officer sold 19,442 for $7.04, making the entire transaction worth $136,872. This insider now owns 0 shares in total.
Galectin Therapeutics Inc (GALT) Performance Highlights and Predictions
As on 12/31/2024, Multinational firm has announced its last quarter scores, in which it reported -0.19 earnings per share (EPS) for the period falling under the consensus outlook (set at -0.16) by -0.03.
According to the Wall Street analysts, stocks earnings will be around 35.53% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 16.03% during the next five years compared to -23.89% drop over the previous five years of trading.
Galectin Therapeutics Inc (NASDAQ: GALT) Trading Performance Indicators
Galectin Therapeutics Inc (GALT) is currently performing well based on its current performance indicators. A quick ratio of 0.09 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.59, a number that is poised to hit -0.10 in the next quarter and is forecasted to reach -0.41 in one year’s time.
Technical Analysis of Galectin Therapeutics Inc (GALT)
Let’s dig in a bit further. During the last 5-days, its volume was 1.35 million. That was better than the volume of 0.42 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 45.71%.
During the past 100 days, Galectin Therapeutics Inc’s (GALT) raw stochastic average was set at 24.97%, which indicates a significant increase from 17.42% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.71 in the past 14 days, which was higher than the 0.42 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.54, while its 200-day Moving Average is $3.35. However, in the short run, Galectin Therapeutics Inc’s stock first resistance to watch stands at $4.87. Second resistance stands at $5.37. The third major resistance level sits at $5.90. If the price goes on to break the first support level at $3.84, it is likely to go to the next support level at $3.31. Assuming the price breaks the second support level, the third support level stands at $2.81.
Galectin Therapeutics Inc (NASDAQ: GALT) Key Stats
Market capitalization of the company is 282.42 million based on 64,473K outstanding shares. Right now, sales total 0 K and income totals -47,050 K. The company made 0 K in profit during its latest quarter, and -8,180 K in sales during its previous quarter.
